ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2449

Patient Characteristics, Treatment and Prognosis in Patients with Neuromyelitis OpticaSpectrum Disorder Coexisting with Systemic Lupus Erythematosus or Sjögren’s Syndrome: An Analysis Using Japanese Inpatient Database
Abstract Number: 0153

Patient Experience and Implementation of an Electronic Patient-Reported Outcome Measures (ePROM) System for Remote Monitoring in BIOBADASER
Abstract Number: 1250

Patient Perceptions of the National Tele-Rheumatology Program: A Mixed Methods Study
Abstract Number: 1265

Patient Portal Awareness and Utilization Across Diverse Rheumatology Populations
Abstract Number: 0370

Patient Preferences for Treatments of Rheumatoid Arthritis: A Discrete Choice Experiment Evaluating Preference for Advanced Drug Therapies and Neuroimmune Modulation Device
Abstract Number: 1253

Patient Reported Outcome Measures: Assessing Resident Physician Acceptance of the Routine Assessment of Patient Index Data 3 Survey and its Impact on Physician-Patient Relationship
Abstract Number: 1267

Patient Reported Outcomes Predict Subsequent Treatment Intensification Among Rheumatoid Arthritis Patients: Longitudinal PRO Measurement Using a Mobile Health App
Abstract Number: 0175

Patient Satisfaction with a New Patient Video Triage Program
Abstract Number: 1149

Patient Symptom State Demonstrates Validity for the Assessment of Disease Activity and Patient-reported Outcomes in Adults with SAPHO and Chronic Nonbacterial Osteomyelitis – A Longitudinal Response Profile Analysis in The SAPHO-CNO Study
Abstract Number: 2561

Patient-Centricity: The Keystone to Recruitment and Retention of Research Participants for the Lupus Landmark Study and the Success of the Lupus Nexus
Abstract Number: 2508

Patient-Reported Outcomes in ANCA-Associated Vasculitis: Early Findings from a Prospective Real-World Cohort
Abstract Number: 2539

Patient-reported outcomes in patients with polymyalgia rheumatica under rheumatology care: baseline data from the ENRICH-PMR cohort
Abstract Number: 2384

Patient-Reported Quality of Life in SLE: Association with Biomarker-Derived Disease Activity Index (L-DAI) and hSLEDAI in a Prospective Cohort
Abstract Number: 0594

Patients with SLE Have an Increased Bisphenol A Methylation Score Linked to SLE Risk Genes and Immune Response Pathways
Abstract Number: 2290

Patterns and Predictors of Clinical Improvement in Patients with Sjögren’s Disease: A Longitudinal Analysis of ESSDAI and ESSPRI Improvements

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].